Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
Pt
CAS Number:
Molecular Weight:
195.08
NACRES:
NA.23
PubChem Substance ID:
UNSPSC Code:
12141734
EC Number:
231-116-1
MDL number:
assay
99.99% trace metals basis
form
powder (coarse)
reaction suitability
core: platinum
resistivity
10.6 μΩ-cm, 20°C
bp
3827 °C (lit.)
mp
1772 °C (lit.)
density
21.45 g/cm3 (lit.)
SMILES string
[Pt]
InChI
1S/Pt
InChI key
BASFCYQUMIYNBI-UHFFFAOYSA-N
Application
- Towards a comprehensive understanding of platinum dissolution in acidic media: This study explores the dissolution behavior of platinum in acidic conditions, offering insights important for material scientists working on catalyst design and durability (Topalov et al., 2014).
- Platinum-based drugs for cancer therapy and anti-tumor strategies: This article discusses the development and mechanisms of platinum-based chemotherapy agents, critical for drug discovery chemists focusing on cancer treatment (Zhang et al., 2022).
- Mastering the surface strain of platinum catalysts for efficient electrocatalysis: This research delves into the manipulation of surface strain in platinum catalysts to enhance their efficiency, pertinent for material science applications in energy conversion (He et al., 2021).
signalword
Danger
hcodes
Hazard Classifications
Flam. Sol. 1
Storage Class
4.1B - Flammable solid hazardous materials
wgk
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type P3 (EN 143) respirator cartridges
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Tao Xiong et al.
Journal of biomedical nanotechnology, 9(2), 274-280 (2013-05-01)
Noninvasive molecular fluorescence imaging in vivo which combines Optical imaging with genetic marker technology can real time monitor the development of tumor, through the use of human adenoid cystic carcinoma cell (ACC-M) and lung carcinoma cells SPC-A1 were thansfected by
Hiroaki Akamatsu et al.
Japanese journal of clinical oncology, 43(6), 664-668 (2013-04-16)
Interstitial lung disease associated with gefitinib is a critical adverse reaction. When geftinib was administered to EGFR-unknown patients, the interstitial lung disease incidence rate was approximately 3-4% in Japan, and usually occurs during the first 4 weeks of treatment. However
Downregulation of glutathione transferase π sensitizes lymphoma/leukaemia cells to platinum-based chemotherapy.
Jianli Chen et al.
British journal of haematology, 162(1), 135-137 (2013-04-12)
Global Trade Item Number
| SKU | GTIN |
|---|---|
| 204048-1G | 04061826741030 |
